Advertisement

International Urology and Nephrology

, Volume 45, Issue 2, pp 553–560 | Cite as

Prevalence of abnormal urinary albumin excretion in elderly people: a Spanish survey

  • N. R. RoblesEmail author
  • F. J. Felix
  • D. Fernandez-Berges
  • J. Perez-Castán
  • M. J. Zaro
  • L. Lozano
  • P. Alvarez-Palacios
  • A. Garcia-Trigo
  • V. Tejero
  • Y. Morcillo
  • A. B. Hidalgo
Nephrology - Original Paper

Abstract

Objectives

HERMEX is a population-based study, which tries to evaluate the prevalence of cardiovascular risk factors in the population of Extremadura, Spain. This report provides the data concerning albuminuria in the elderly people recruited in the survey.

Design and methods

3,402 subjects were randomly selected from the database of the Health Care System of Extremadura. The final sample included 2,813 subjects (mean age 51.2 years, 53.5 % female). Urinary albumin excretion rate (UAER) in the first morning urine sample was analyzed. Albuminuria was diagnosed when UAER (albumin-to-creatinine ratio) was ≥22 mg/g in men or ≥31 mg/g in women.

Results

The prevalence of abnormal UAER in the elderly population was 10.9 % (microalbuminuria: 8.9 %; overt proteinuria: 1.8 %). The younger subjects showed a lower prevalence of microalbuminuria (3.4 %, p < 0.001). Elderly patients showed a higher prevalence of cardiovascular risk factors than the younger ones. The elderly had higher systolic blood pressure and pulse pressure than the younger ones. Furthermore, the elderly subjects had lower plasma levels of HDL cholesterol, but higher triglycerides, glucose, creatinine, and glycosylated hemoglobin; no differences were found for total and LDL cholesterol. When the prevalence of causes of microalbuminuria was compared between age groups, we found a sharp increase in diabetic and, especially, hypertensive patients in the elderly group. The multivariate analysis showed an independent association of microalbuminuria with systolic blood pressure and plasma creatinine.

Conclusions

A high prevalence of abnormal UAER in elderly people was detected in a randomly selected sample of Spanish general population. In most elderly patients, microalbuminuria was associated with high blood pressure and, less frequently, with diabetes mellitus.

Keywords

Microalbuminuria Cardiovascular risk factors Hypertension Elderly 

References

  1. 1.
    Dinneen SF, Gerstein HC (1997) The association of micro albuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 157:1413–1418PubMedCrossRefGoogle Scholar
  2. 2.
    Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) UKPDS group: development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232PubMedCrossRefGoogle Scholar
  3. 3.
    Mogensen CE (2003) Micro albuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 254:45–66PubMedCrossRefGoogle Scholar
  4. 4.
    Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426PubMedCrossRefGoogle Scholar
  5. 5.
    Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch- Johnsen K (2000) Arterial hypertension, micro albuminuria, and risk of ischemic heart disease. Hypertension 35:898–903PubMedCrossRefGoogle Scholar
  6. 6.
    Bigazzi R, Bianchi S, Baldari D, Campese VM (1998) Micro albuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325–1333PubMedCrossRefGoogle Scholar
  7. 7.
    Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al (2002) For the prevention of renal and vascular end stage disease (PREVEND) study group. Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRefGoogle Scholar
  8. 8.
    Robles NR, Mena C, Velasco J, Angulo E, Garrote T, Garcia Gallego F (2008) En representación de los investigadores del estudio MICREX Riesgo cardiovascular asociado a micro albuminuria en pacientes diabéticos y en pacientes con hipertensión arterial. Med Clin (Barc) 130:206–209CrossRefGoogle Scholar
  9. 9.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh report of joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572Google Scholar
  10. 10.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al (2007) Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187PubMedCrossRefGoogle Scholar
  11. 11.
    Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K et al (2009) Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54:205–226PubMedCrossRefGoogle Scholar
  12. 12.
    Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M et al (2002) Micro albuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 39:445–459PubMedCrossRefGoogle Scholar
  13. 13.
    Robles NR, Felix FJ, Fernandez-Berges D, Perez-Castán JF, Zaro MJ, Lozano L, et al. Prevalence of abnormal urinary albumin excretion in a population based study in Spain: results from the Hermex study. Eur J Clin Invest. (in press)Google Scholar
  14. 14.
    Simera I, Moher D, Hoey J, Schulz KF, Altman DG (2010) A catalogue of reporting guidelines for health research. Eur J Clin Invest 40:35–53PubMedCrossRefGoogle Scholar
  15. 15.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239PubMedCrossRefGoogle Scholar
  16. 16.
    Banegas JR, Rodriguez-Artalejo F, Ruilope LM, Graciani A, Luque M et al (2002) Hypertension magnitude and management in the elderly population of Spain. J Hypertens 20:2157–2164PubMedCrossRefGoogle Scholar
  17. 17.
    Gutzwiller F, Keil U, Tuomilehto J (1990) Societal and community effects on blood pressure. In: Laragh JH, Brenner BM (eds) Hypertension: pathophysiology, diagnosis, and management. Raven Press Publishers, New York, pp 147–158Google Scholar
  18. 18.
    Roberts J, Maurer K (1977) Blood pressure levels of persons 6–74 Years. United States, 1971–1974. Vital and health statistics, Series 11, No. 203. Washington, DC: US Dept of Health, Education, and Welfare, 1–103Google Scholar
  19. 19.
    Bigazzi R, Bianchi S (1995) Micro albuminuria as a marker of cardiovascular and renal disease in essential hypertension. Nephrol Dial Transplant 10(Suppl 6):10–14PubMedCrossRefGoogle Scholar
  20. 20.
    Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla L et al (1989) Micro albuminuria and casual and ambulatory blood pressure monitoring in normotensive and in patients with borderline and mild essential hypertension. Am J Hypertens 2:259–261PubMedGoogle Scholar
  21. 21.
    Cerasola G, Cottone S, Mule G, Nardi E, Mangano MT, Andronico G et al (1996) Micro albuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 14:915–920PubMedCrossRefGoogle Scholar
  22. 22.
    Hermida RC, Ayala DE, Calvo C (2007) Optimal timing for antihypertensive dosing: focus on valsartan. Ther Clin Risk Manag 3:119–131PubMedCrossRefGoogle Scholar
  23. 23.
    Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S et al (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Micro albuminuria Prevention (ROADMAP) study. Diabetologia 53:49–57PubMedCrossRefGoogle Scholar
  24. 24.
    Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V et al (2002) Increase in nocturnal blood pressure and progression to micro albuminuria in type 1 diabetes. N Engl J Med 347:797–805PubMedCrossRefGoogle Scholar
  25. 25.
    Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH (2005) Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 68:1250–1257PubMedCrossRefGoogle Scholar
  26. 26.
    Afsar B, Sezer S, Elsurer R, Ozdemir FN (2007) Is HOMA index a predictor of nocturnal non dipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit 12:133–139PubMedCrossRefGoogle Scholar
  27. 27.
    Canonico V, Caprio LD, Vigorito C, Forgione L, Tedeschi C, Guanni P et al (1990) Differences in blood pressure profile between young and elderly hypertensive patients. J Hum Hypertens 4:405–440PubMedGoogle Scholar
  28. 28.
    James MA, Fotherby MD, Potter JF (1994) Clinical correlates of left ventricular mass in elderly hypertensives. J Hum Hypertens 8:409–415PubMedGoogle Scholar
  29. 29.
    Nakatsuka H, Imai Y, Abe K, Nagai K, Ikeda M, Satoh H et al (1991) Population study of ambulatory blood pressure in a rural community in Northern Japan. Tohoku I Exp Med 163:119–127CrossRefGoogle Scholar
  30. 30.
    Fotherby MD, Potter JF (1995) Twenty-four-hour ambulatory blood pressure in old and very old subjects. J Hypertens 13:1742–1746PubMedCrossRefGoogle Scholar
  31. 31.
    King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRefGoogle Scholar
  32. 32.
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295:1549–1555PubMedCrossRefGoogle Scholar
  33. 33.
    Zimmet P, Alberti KGM, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRefGoogle Scholar
  34. 34.
    Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H et al (2001) Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 24:1936–1940PubMedCrossRefGoogle Scholar
  35. 35.
    Pollock CA, Poronnik P (2007) Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 16:359–364PubMedCrossRefGoogle Scholar
  36. 36.
    Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA et al (1999) Chronic kidney disease awareness prevalence, and trends among US adults, to 2000. J Am Soc Nephrol 2005(16):180–188Google Scholar
  37. 37.
    Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 41:1–12PubMedCrossRefGoogle Scholar
  38. 38.
    Bakker AJ (1999) Detection of macro albuminuria—Receiver operating curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 22:307–313PubMedCrossRefGoogle Scholar
  39. 39.
    Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G (2002) Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 39:1183–1189PubMedCrossRefGoogle Scholar
  40. 40.
    Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ (2005) Evaluation of tests for micro albuminuria screening in patients with diabetes. Nephrol Dial Transplant 20:2402–2407PubMedCrossRefGoogle Scholar
  41. 41.
    Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT (2005) Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525–2530PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • N. R. Robles
    • 1
    • 7
    Email author
  • F. J. Felix
    • 2
  • D. Fernandez-Berges
    • 3
    • 4
    • 5
  • J. Perez-Castán
    • 4
  • M. J. Zaro
    • 5
  • L. Lozano
    • 6
  • P. Alvarez-Palacios
    • 3
  • A. Garcia-Trigo
    • 3
  • V. Tejero
    • 3
  • Y. Morcillo
    • 3
  • A. B. Hidalgo
    • 3
  1. 1.Cátedra de Riesgo Vascular, Facultad de MedicinaUniversidad de SalamancaSalamancaSpain
  2. 2.Centro de Salud Villanueva de la Serena-NorteVillanueva de la Serena, BadajozSpain
  3. 3.FUNDESALUD, Programa de Investigación en Enfermedades CardiovascularesUnidad de Investigación Don Benito-Villanueva de la SerenaBadajozSpain
  4. 4.Gerencia de Area de Don Benito-Villanueva de la SerenaBadajozSpain
  5. 5.Hospital de Don Benito-Villanueva de la SerenaBadajozSpain
  6. 6.Centro de Salud MeridaBadajozSpain
  7. 7.Unidad de Hipertensión ArterialHospital Infanta CristinaBadajozSpain

Personalised recommendations